All In Biotech

Drug Trial Radar · NCT02564523

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa

Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,075 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,075

Actual

Start

Nov 6, 2015

Primary completion

Feb 12, 2019

Study completion Feb 12, 2019

Sponsor

Lead sponsor
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
EBOVAC2 Consortium; Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz
First posted
Sep 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 4 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study will include healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata.

Conditions

  • Hemorrhagic Fever, Ebola

Interventions

  • Ad26.ZEBOVBiological

    One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)

  • MVA-BN-FiloBiological

    One 0.5 mL IM injection of (1x10\*8 infectious units)

  • PlaceboBiological

    One 0.5 mL IM injection of 0.9% saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (Day 29)Time frame: Up to 28 days post-dose 1 (Day 29)
  2. Number of Participants With Adverse Events (AEs) (28-Day Interval)Time frame: Up to 28 days post-dose 2 (Day 57 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])
  3. Number of Participants With Adverse Events (56-day Interval)Time frame: Up 28 days post-dose 2 (Day 85 for Cohorts 1, 2a, 2b and 3 [56-Day Interval])
  4. Number of Participants With Adverse Events (84-day Interval)Time frame: Up to 28 days post-dose 2 (Day 113 for Cohort 1 [84-Day Interval])
  5. Number of Participants With Adverse Events Post-dose 3 (Day 393)Time frame: Up 28 days post-dose 3 (Day 393)
  6. Number of Participants With Serious Adverse EventsTime frame: Up to 3 years and 3 months
  7. Number of Participants With Immediate Reportable Events (IREs)Time frame: Up to 3 years and 3 months
  8. Number of Participants With Solicited Local Adverse Events (Day 8)Time frame: 7 days post-dose 1 (Day 8)
  9. Number of Participants With Solicited Local Adverse Events (28-day Interval)Time frame: Up to 7 days post-dose 2 (Day 36 for Cohort 1, 2a, 2b and 3 [28-Day Interval])
  10. Number of Participants With Solicited Local Adverse Events Post-dose 2 (56-day Interval)Time frame: Up to 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])
  11. Number of Participants With Solicited Local Adverse Events (84-day Interval)Time frame: Up to 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])
  12. Number of Participants With Solicited Local Adverse Events (Day 372)Time frame: Up 7 days post-dose 3 (Day 372)
  13. Number of Participants With Solicited Systemic Adverse Events (Day 8)Time frame: Up to 7 days post-dose 1 (Day 8)
  14. Number of Participants With Solicited Systemic Adverse Events (28-Day Interval)Time frame: Up to 7 days post-dose 2 (Day 36 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])
  15. Number of Participants With Solicited Systemic Adverse Events (56-Day Interval)Time frame: Up 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])
  16. Number of Participants With Solicited Systemic Adverse Events (84-Day Interval)Time frame: Up 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])
  17. Number of Participants With Solicited Systemic Adverse Events (Day 372)Time frame: Up to 7 days post-dose 3 (Day 372)

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    BoboDioulasso, Burkina Faso

  • Site not named

    Ouagadougou, Burkina Faso

  • Site not named

    Abidjan, Côte d’Ivoire

  • Site not named

    Toupah/Ousrou, Côte d’Ivoire

  • Site not named

    Nairobi, Kenya

  • Site not named

    Entebbe, Uganda

  • Site not named

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.